These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36725768)

  • 21. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
    Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR
    Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study.
    Witte T; Kiltz U; Haas F; Riechers E; Prothmann U; Adolf D; Holland C; Rössler A; Soppa U; Fritz B; Götz K; Krüger K;
    Clin Exp Rheumatol; 2024 Mar; 42(3):726-735. PubMed ID: 37976112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.
    Kakehasi AM; Radominski SC; Baravalle MD; Palazuelos FCI; Garcia-Garcia C; Arruda MS; Curi M; Liu J; Qiao M; Velez-Sanchez P; Vargas JI
    Clin Rheumatol; 2023 May; 42(5):1249-1258. PubMed ID: 36715850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
    Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
    RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
    Combe B; Allanore Y; Alten R; Caporali R; Durez P; Iannone F; Nurmohamed MT; Toumi M; Lee SJ; Kwon TS; Noh J; Park G; Yoo DH
    Arthritis Res Ther; 2021 Apr; 23(1):119. PubMed ID: 33863352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
    Strand V; Reaney M; Chen CI; Proudfoot CW; Guillonneau S; Bauer D; Mangan E; Graham NM; van Hoogstraten H; Lin Y; Pacheco-Tena C; Fleischmann R
    RMD Open; 2017; 3(1):e000416. PubMed ID: 28326189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.
    Choy E; Bykerk V; Lee YC; van Hoogstraten H; Ford K; Praestgaard A; Perrot S; Pope J; Sebba A
    Rheumatology (Oxford); 2023 Jul; 62(7):2386-2393. PubMed ID: 36413080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.
    Gabay C; Msihid J; Zilberstein M; Paccard C; Lin Y; Graham NMH; Boyapati A
    RMD Open; 2018; 4(1):e000607. PubMed ID: 29556418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
    Lee YH; Song GG
    Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
    Mease PJ; Lertratanakul A; Papp KA; van den Bosch FE; Tsuji S; Dokoupilova E; Keiserman MW; Bu X; Chen L; McCaskill RM; Zueger P; McDearmon-Blondell EL; Pangan AL; Tillett W
    Rheumatol Ther; 2021 Jun; 8(2):903-919. PubMed ID: 33913086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
    Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
    Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
    Fleischmann R; Blanco R; Van den Bosch F; Bessette L; Song Y; Penn SK; McDearmon-Blondell E; Khan N; Chan K; Mysler E
    Rheumatol Ther; 2024 Jun; 11(3):599-615. PubMed ID: 38498140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.